SUPERNUS PHARMACEUTICALS, INC. Payments to Acquire Debt Securities, Available-for-sale
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Payments to Acquire Debt Securities, Available-for-sale of $128.44 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-03
- SUPERNUS PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $50.00M, a 64.43% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $78.44M, a 33.84% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $90.20M, a 37.97% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $126.63M, a 43.70% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for fiscal 2025 was $475.94M, a 30.82% decline from fiscal 2024.
- SUPERNUS PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for fiscal 2024 was $688.01M, a 577.04% increase from fiscal 2023.
- SUPERNUS PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for fiscal 2023 was $101.62M, a 75.03% decline from fiscal 2022.
- SUPERNUS PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for fiscal 2022 was $406.99M, a 30.62% increase from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $50.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $128.44M 10-Q · filed 2026-08-03 | $218.64M derived: sum of 3 quarters · filed 2026-08-03 | $345.27M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $78.44M 10-Q · filed 2026-05-05 | $168.64M derived: sum of 2 quarters · filed 2026-05-05 | $295.27M derived: sum of 3 quarters · filed 2026-05-05 | $435.82M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $90.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $216.83M derived: sum of 2 quarters · filed 2026-03-02 | $357.38M derived: sum of 3 quarters · filed 2026-08-03 | $475.94M 10-K · filed 2026-03-02 |
| 2025-09-30 | $126.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $267.18M derived: sum of 2 quarters · filed 2026-08-03 | $385.74M 10-Q · filed 2025-11-06 | $531.15M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $140.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $259.11M 10-Q · filed 2026-08-03 | $404.52M derived: sum of 3 quarters · filed 2026-08-03 | $629.45M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $118.56M 10-Q · filed 2026-05-05 | $263.96M derived: sum of 2 quarters · filed 2026-05-05 | $488.89M derived: sum of 3 quarters · filed 2026-05-05 | $612.87M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $145.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $370.33M derived: sum of 2 quarters · filed 2026-03-02 | $494.31M derived: sum of 3 quarters · filed 2026-03-02 | $688.01M 10-K · filed 2026-03-02 |
| 2024-09-30 | $224.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $348.91M derived: sum of 2 quarters · filed 2025-11-06 | $542.61M 10-Q · filed 2025-11-06 | $644.23M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $123.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $317.68M 10-Q · filed 2025-08-05 | $419.30M derived: sum of 3 quarters · filed 2026-03-02 | $419.30M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $193.70M 10-Q · filed 2025-05-06 | $295.32M derived: sum of 2 quarters · filed 2026-03-02 | $295.32M derived: sum of 3 quarters · filed 2026-03-02 | $295.32M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $101.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $101.62M derived: sum of 2 quarters · filed 2026-03-02 | $101.62M derived: sum of 3 quarters · filed 2026-03-02 | $101.62M 10-K · filed 2026-03-02 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $0.00 derived: sum of 2 quarters · filed 2024-11-04 | $0.00 10-Q · filed 2024-11-04 | $66.33M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $0.00 10-Q · filed 2024-08-06 | $66.33M derived: sum of 3 quarters · filed 2025-02-25 | $200.49M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-08 | $66.33M derived: sum of 2 quarters · filed 2025-02-25 | $200.49M derived: sum of 3 quarters · filed 2025-02-25 | $308.93M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $66.33M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $200.49M derived: sum of 2 quarters · filed 2025-02-25 | $308.93M derived: sum of 3 quarters · filed 2025-02-25 | $406.99M 10-K · filed 2025-02-25 |
| 2022-09-30 | $134.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $242.60M derived: sum of 2 quarters · filed 2023-11-08 | $340.67M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $108.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $206.50M 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $98.06M 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $311.57M 10-K · filed 2023-03-09 | |||
| 2020-12-31 | $95.89M 10-K · filed 2023-03-09 | |||
| 2019-12-31 | $409.71M 10-K · filed 2022-04-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |